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Abstract
Background: A representative cross-sectional study showed that chronic itch (lasting for a minimum of 6 weeks)
affects 25.2 % (point prevalence) of hemodialysis (HD) patients. Pathophysiology and etiology of chronic itch (CI) in
HD are still unclear.
Methods: We investigated 860 HD patients from a representative randomly selected cluster-sample considering the
regional distributions of dialysis units in GermanyThe current analyses report comorbidities, laboratory values and
dialysis characteristics of HD patients in relation to CI.
Results: Diabetes was the only comorbidity that was associated with the occurrence of itch but interestingly with
less CI. Except for creatinine, phosphorus, and parathormone, there were no significant associations between the
occurrence and characteristics of CI and any laboratory value. Kt/V was not associated with the presence of CI.
Patients dialyzed with polyarylethersulfone-membrane showed significantly more CI in all prevalence estimates and
those dialyzed with polysulfone-membrane were significantly less affected by CI.
Conclusions: Long-term follow-up studies will show if the type of dialysis membrane influences the development of
CI in HD patients. It is most likely that several factors e.g. elevated parathormone, origin of end stage renal disease
(ESRD), type of dialysis membrane, and a neuropathic component all contribute to the occurrence of CI in HD patients.
Future research should consider a multifactorial origin of itch in HD.
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Background
GEHIS (German Epidemiological Hemodialysis Itch
Study) is a cross-sectional study that investigated 860
hemodialysis (HD) patients from a randomly selected
cluster-sample (considering the regional distribution of
dialysis units in Germany) aiming to identify different
prevalence estimates of chronic itch [1]. According to
the international classification, chronic itch (CI) is
defined as itch lasting for 6 weeks and longer [2]. This
classification had never been applied in a cohort of
hemodialysis patients except for GEHIS [1]. Our first
analyses revealed that CI affects 25.2 % (point preva-
lence) of HD patients. 35.2 % reported to have suffered
from chronic itch (CI) at least once in their life (lifetime
prevalence) and 27.2 % reported CI within the past
12 months [1]. CI was significantly less prevalent in
patients with an etiology of secondary glomeruloneph-
ritis. There was a significant association of the time since
HD treatment started and the occurrence of CI. General
health status and health-related quality of life (HRQOL)
were significantly more impaired in those suffering from
CI [1]. All this demonstrates that CI in HD patients is a
frequent, long-lasting burden significantly impairing
patient’s health.
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The role of comorbidities in the occurrence of itch
in HD patients is unclear and has so far only been
investigated for selected comorbidities [3–5]. Single
studies investigated some abnormalities of laboratory
parameters in HD patients suffering from itch e.g.
parathormone (PTH), calcium, phosphorus, but the
role of them in the occurrence and the intensity of CI
in HD patients is still unclear [3, 5–9]. So far, there is
no systematic investigation on dialyzer membrane use
and the development of CI. Smaller studies hint to
conflicting results regarding the role of dialyzer mem-
branes [10–12]. The current analyses investigated possible
associations of medical (etiology of end-stage renal disease
(ESRD), comorbidities), laboratory and dialysis character-
istics (time, duration, dialyzer membrane, anticoagulation)
with the occurrence and characteristics of CI.
Methods
The study (GEHIS) was established as a prospective obser-
vational prevalence study in 2012 and was conducted
between May and September 2013. Eligible patients were
diagnosed with ESRD and were undergoing chronic
hemodialysis (HD) treatment. The study was established
according to the guidelines of good clinical practice and
conducted in full accordance with the protocols of the
World Medical Association’s Declaration of Helsinki.
Ethical approval was obtained from the University of
Heidelberg, Germany (No. S-648/2012). Patients gave
their written informed consent. All results were reported
in line with the “Strengthening the Reporting of Observa-
tional Studies in Epidemiology (STROBE)” recommenda-
tions [13]. A detailed description of the study, its design
and the study instruments are provided elsewhere [1].
The current analyses are based on a data set obtained
in every patient including the etiology of ESRD (primary
glomerulonephritis, secondary glomerulonephritis in-
cluding systemic diseases such as diabetes mellitus, py-
elonephritis/interstitial nephritis, hypertensive nephritis,
congenital renal disease, unknown origin, others) and
sociodemographic data (sex, age, occupational status,
education, marital status, ethnic origin) 1]. Itching was
assessed asking for current CI, CI within the last
12 months and CI ever in life as well as characteristics
of CI [1]. Severity of itch was measured using a visual
analogue scale (VAS) ranging from 0 (no itching) to 10
(maximum imaginable itching) which proved to be a
valuable method of itch assessment [14].
Routine laboratory investigations were usually per-
formed every four weeks (except for PTH). Laboratory
values closest to the date of investigation were transferred
from the laboratory chart: leukocytes (G/l), haemoglobin
(Hb) (g/dl), haematocrit (Hct) (%), platelets (G/l), albumin
(g/dl), creatinine (mg/dl), urea (mg/dl), glucose (mg/dl),
sodium (mmol/l), potassium (mmol/l), calcium (mmol/l),
phosphate (mmol/l), C-reactive-protein (CRP) (mg/dl),
iPTH (ng/L). PTH values older than 6 month were not
considered. Different assays have been used for PTH
measurement with different reference values. This was
considered in our analyses. The following laboratory
values were also collected if available in the chart: magne-
sium, alkaline phosphatase, transaminases, gamma-GT,
serum albumin, IgE, eosinophils, hepatitis and HIV-status.
An adapted version of the Charlson Comorbidity
Index was used to assess comorbidities in patients with
ESRD [15, 16]. Additional comorbidities of the patients
if present were assessed according to the patients’ charts.
Kt/V was extracted from the laboratory files selecting
the last available value within the last 4 months. Calcula-
tion of Kt/V was performed in accordance to the
German quality assurance regulation (single pool) using
the Daugirdas approximation by each centre [17]. The
following dialysis parameters were assessed: start and
weekly duration of HD treatment, mean dialysate
temperature, type of dialysis membrane (see Table 4),
disposable sterilisation method (beta radiation, gamma
radiation, ethylene oxide and steam), type of membrane
flux (low-flux, high-flux), type of heparin (unfractionated
heparin, low molecular heparin, other anticoagulants)
used during HD and pre-flushing.
Statistical analyses
For data management, a Microsoft Access 2003 database
was used. Data entry was conducted twice by two inde-
pendent persons. To maximize data quality, all observed
random or potentially systematic inconsistencies within
resulting data were solved. Statistical analyses were per-
formed using SPSS (version 20) for Windows. Nominal
and ordinal data were analyzed by computing absolute
(n) and relative frequencies (%), respectively, and 95 %
confidence intervals were computed. First chi2 statistics
were used to identify variables that were significantly
associated with CI in univariate analysis. P-values below
0.05 were considered significant. Comparisons between
HD patients suffering from CI and HD patients not
affected were conducted by independent t-tests/ANOVA
for the continuous variables (e.g. laboratory values)
and by chi2-test for binary distributions. Associations
between laboratory findings and the occurrence of CI
are reported by Pearson’s correlation coefficients. To
deal with the problem of multiple testing when analyz-
ing differences in laboratory values, a Bonferroni cor-
rection was conducted, setting the significance cut-off
at α/n.
Results
The study sample has been described in detail else-
where [1]. 860 HD patients were included into GEHIS,
57.2 % were male. The mean age was 67.2 years
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(standard deviation (SD) 13.4). At the time of the inves-
tigation, 25.2 % (95 %-confidence interval (95 %-CI)
22.4–28.1) suffered from CI (point prevalence, whereby
the 12-month prevalence was 27.2 % (95 %-CI 24.1–
30.3) and the lifetime prevalence was 35.2 % (95 %-CI
31.9–38.3) [1].
Comorbidities and chronic itch
Leading comorbidities according to Charlson Comorbid-
ity Index adapted for patients with ESRD were diabetes
mellitus in 38.0 % (n = 327), congestive heart failure in
24.7 % (n = 212) and peripheral arterial occlusive disease
in 21.2 % (n = 182) (Table 1) [16].
Evaluating the Charlson comorbidities separately,
diabetes mellitus with and without complications was
significantly associated with all prevalence estimates of
CI. HD patients affected by diabetes mellitus suffered
significantly less from CI. Any further significant associ-
ations between the prevalence of CI and comorbidities
were not identified. Mean score for Charlson comorbid-
ity index adapted for patients with ESRD was 4.3 (SD
4.5) (Table 1). There were no significant associations
with the prevalence of CI, neither with the mean score
of the Charlson Comorbidity index nor when regarding
grouped scores. 87.6 % (n = 753) of the HD patients
suffered from arterial hypertension, 93.7 % (n = 806)
Table 1 Comorbidities according to Charlson adapted for patients with ESRD and additional concomitant diseases (n = 860)
Chronic Itch (all prevalence estimates) Total
Yes, % (n) No, % (n) (n = 860)
(n = 307) (n = 553)
Comorbidities (according to Charlson) Relative frequency, % (n) Relative frequency, % (n) Relative frequency, % (n)
Myocardial infarction 16.6 (51) 16.8 (93) 16.7 (144)
Congestive heart failure 22.8 (70) 25.7 (142) 24.7 (212)
Peripheral vascular disease 20.0 (62) 21.7 (120) 21.2 (182)
Cerebral vascular disease 12.7 (39) 15.7 (87) 14.7 (126)
Dementia 1.6 (5) 1.8 (10) 1.7 (15)
Chronic lung disease 20.8 (64) 18.6 (103) 19.4 (167)
Rheumatological disease 2.9 (9) 2.9 (16) 2.9 (25)
Peptic ulcer disease 7.8 (24) 8.5 (47) 8.3 (71)
Hemiplegia 1.3 (4) 2.5 (14) 2.1 (18)
Diabetes without complications 30.9 (95)* 42.0 (232)** 38.0 (327)
Diabetes with complications 22.8 (70)* 31.8 (167)** 28.6 (246)
Mild liver disease 5.2 (16) 4.3 (24) 4.7 (40)
Moderate/severe liver disease 2.0 (6) 1.4 (8) 1.6 (14)
Metastatic disease 13.0 (40) 12.1 (67) 12.4 (107)
Leukemia 0.3 (1) 0.2 (1) 0.2 (2)
Lymphoma 3.9 (12) 3.1 (17) 3.4 (29)
Human immunodeficiency virus - - -
Charlson Comorbidity Index, mean ± SD 4.1 ± 4.4 4.4 ± 4.6 4.3 ± 4.5
Charlson score 0 25.7 (79) 23.3 (129) 24.2 (208)
Charlson score 1–2 18.9 (58) 17.5 (97) 18.0 (155)
Charlson score 3–4 19.5 (60) 20.6 (114) 20.0 (174)
Charlson score ≥5 35.8 (110) 38.5 (213) 37.6 (323)
Additionally assessed comorbidities
Arterial hypertension 87.6 (269) 87.5 (484) 87.6 (753)
Anemia 95.1 (292) 92.9 (514) 93.7 (806)
Hyperparathyroidism 85.0 (261) 83.2 (460) 83.8 (721)
Dyslipidemia 39.7 (122) 41.4 (229) 40.8 (351)
Osteoporosis 6.2 (19) 5.1 (28) 5.5 (47)
*Significantly lower than average at p < 0.05
**Significantly higher than average at p < 0.05
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from anemia and 83.8 % (n = 721) from hyperparathyr-
oidism. Dyslipidemia was observed in 40.8 % (n = 351),
osteoporosis in 5.5 % (n = 47). These comorbidities did
not show any significant association with the prevalence
of CI (Table 1). None of the investigated patients was
HIV positive or had AIDS.
There were no associations of any comorbidities,
laboratory values, or type of dialyzer membrane used
with the characteristics of itch e.g. localization and
severity of CI.
Laboratory values and chronic itch
All laboratory values are presented in Table 2. 81.9 % of
the HD-patients had PTH levels lower than 500 ng/l and
in 18.1 % PTH levels were 500 ng/l and higher. There
were weak but statistically significant differences in para-
thormone (PTH), creatinine and phosphorus. These
laboratory values were significantly higher in HD
patients suffering from CI. There was no correlation
between the severity of itch (VAS) and the PTH level.
All other laboratory parameters mentioned above were
not included in our analyses because not every dialyses
unit had documented them and therefore the number of
cases was too low (non-routine laboratory parameters).
Dialysis characteristics
According to the current quality criteria on HD treat-
ment in Germany, HD patients undergo at least 4 h HD
dialysis treatment 3 times weekly and HD treatment
aims at a Kt/V of >1.3. The mean dialysis efficacy (Kt/V)
was 1.5 (SD 0.3, min 0.5, max 3.1) (Tables 2 and 3). The
mean dialysis time per week was 12.9 h (SD 1.3 h)
(Table 3). The mean time on HD was 58 months
(4.8 years) (SD 56.2 months). HD patients affected by CI
(all prevalence estimates) were significantly longer on
HD (58 months, SD 56.2 months versus 50.8 SD
45.5 months) [1].
Regarding the methods of dialyzing used, HD treat-
ment was the leading procedure (80.0 %), followed by
post-dilution hemodiafiltration (17.2 %) and pre-
dilution hemodiafiltration (2.0 %). A significant associ-
ation of the dialyzing method and the occurrence of CI
did not occur. Also differences in dialyzers used (high-
flux 88.7 % and low-flux 11.3 %) were not significantly
associated with the occurrence of CI. However, the dif-
ference in sample size of these two groups may explain
why we could not detect significant differences.
Steam was the most commonly used method of
sterilization in both blood lines (43.9 %) and dialyzers
(79.5 %) (Table 3). In blood lines, the second most fre-
quent method of sterilization was beta radiation (37.9 %),
in dialyzers gamma radiation (18.2 %). There were no
significant associations between the procedure of
sterilization and the occurrence of CI. Regarding the
mean temperature of the dialysate (36.4 °C), there were
no significant differences in patients affected and not
affected by CI.
Anticoagulation was documented for 818 patients. Out
of those, unfractionated heparin (UFH) was used for
anticoagulation in 81.7 % (n = 668) and low molecular
weight heparin in 16.5 % (n = 135). 1.8 % received
another medication for anticoagulation (n = 15). There
was no significant association of the type of heparin and
current CI (point prevalence) but low molecular heparin
use was significantly associated with a higher prevalence
of CI ever experienced in life. Multiple testing showed
Table 2 Laboratory values (whole population) in patients with and without chronic itch (n = 860)
Current chronic itch (point prevalence) Total
Yes No (n = 860)
Laboratory value, means ± SD1 Mean ± SD1 Mean ± SD1 Mean ± SD1
Kt(V) 1.5 ± 0.4 1.5 ± 0.3 1.5 ± 0.3
Urea (mg/dl) 127.6 ± 38.8 132.3 ± 36.3 128.8 ± 38.2
CRP (mg/dl) 1.2 ± 2.1 1.3 ± 1.8 1.2 ± 1.9
Parathormone (ng/l) 376.9 * ± 380.2 289.9 * ± 329.4 311.7 ± 344.6
Hemoglobin (g/dl) 11.4 ± 1.3 11.3 ± 1.2 11.3 ± 1.2
Creatinine (mg/dl) 8.9 * ± 2.9 7.8 * ± 2.6 8.1 ± 2.8
Calcium (mmol/l) 2.2 ± 0.2 2.2 ± 0.2 2.2 ± 0.2
Phosphorus (mmol/l) 1.9 * ± 0.6 1.7 * ± 0.5 1.8 ± 0.5
Potassium (mmol/l) 5.3 ± 0.7 5.2 ± 0.7 5.2 ± 0.7
Sodium (mmol/l) 138.6 ± 3.2 138.6 ± 3.6 138.6 ± 3.5
Alkaline phosphatase (U/l) 104.1 ± 65.6 96.2 ± 78.0 98.1 ± 75.1
Serum albumin (g/dl) 3.9 ± 0.4 3.9 ± 0.5 3.9 ± 0.5
1 Standard deviation
* Significantly different at p < 0.004 (Bonferroni correction)
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that CI was significantly more prevalent (all prevalence
estimates) in low molecular heparin use compared to
those patients who received another type of anticoagula-
tion (e.g. point prevalence 31.9 % versus 24.0 %). There
was no significant association between heparin used and
any other factors previously identified e.g. self-reported
dry skin, eczema 1].
The following dialyzer membranes were used: polysul-
fone (63.3 %, n = 544), polyarylethersulfone (24.5 %, n =
211), polyethersulfone (9.9 %, n = 85), polymethylmetha-
crylat (0.8 %, n = 7) and polyacrylonitril (0.1 %, n = 1)
(Table 4). When looking at the lifetime prevalence of CI,
patients dialyzed with a polysulfone membrane were
significantly less affected by CI. Patients dialyzed with
polyarylethersulfone membrane reported significantly
more CI in all prevalence estimates (Table 4). When ask-
ing for the severity of “worst itch” experienced according
to VAS, patients dialyzed on polysulfone reported signifi-
cantly higher values on VAS (6.9 in polysulfone mem-
brane vs. 6.0 when using another membrane). There were
no other significant associations between the type of
membrane and any characteristics of CI.
Previous analyses showed that CI was less prevalent in
those HD patients with secondary glomerulonephritis as
the cause of renal failure [1]. Further analyses grouping all
patients according to their aetiology of renal failure did
Table 3 Dialysis parameters (whole study population) in patients with and without chronic itch (n = 860)
Chronic itch (lifetime prevalence) Total
Yes (n = 307) No (n = 553) (n = 860)
Dialysis vintage Mean Mean Mean
Start of dialysis treatment, months ± SDa 70.4 ± 70.1* 50.8 ± 45.5* 57.5 ± 56.2
Duration of weekly dialysis treatment, hours ± SD 13.0 ± 1.3 12.9 ± 1.3 12.9 ± 1.3
Method of dialysis treatment (n = 851) Relative frequency, % (n) Relative frequency, % (n) Relative frequency, % (n)
Hemodialysis 80.1 (246) 81.3 (442) 80.8 (688)
Online hemodiafiltration (post-dilution) 17.3 (53) 17.1 (93) 17.2 (146)
Online hemodiafiltration (pre-dilution) 2.6 (8) 1.7 (9) 2.0 (17)
Dialyzers used (n = 850)
Low-flux 8.8 (27) 12.7 (69) 11.3 (96)
High-flux 91.2 (279) 87.3 (475) 88.7 (754)
Dialyzer membrane (n = 848)
Polysulfone 57.8 (175)** 66.2 (369) 63.3 (544)
Polyethersulfone 10.2 (31) 9.7 (54) 9.9 (85)
Polyarylethersulfone 29.7 (90)*** 21.7 (121) 24.5 (211)
Polyacrylonitrile - 0.2 (1) 0.1 (1)
Polyester-polymer - -
Polymethylmethacrylate 1.7 (5) 0.4 (2) 0.8 (7)
Sterilization technique, blood lines (n = 852)
Beta radiation 37.5 (115) 38.2 (208) 37.9 (323)
Gamma radiation 17.6 (54) 18.5 (101) 18.2 (155)
Ethylene oxide - - -
Steam 45.0 (138) 43.3 (236) 43.9 (374)
Sterilization technique dialyzer (n = 852)
Beta radiation 0.3 (1) 0.6 (3) 0.5 (4)
Gamma radiation 19.2 (59) 20.6 (112) 20.1 (171)
Ethylene oxide - -
Steam 80.5 (247) 78.9 (430) 79.5 (677)
Dialysate temperature, mean ± SD (°C) (n = 860) 36.4 ± 0.2 36.4 ± 0.3 36.4 ± 0.3
aSD: standard deviation
*Significantly different at p < 0.05
**Significantly lower than average at p < 0.05
***Significantly higher than average at p < 0.05
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not reveal any significant differences in comorbidities, dia-
lysis characteristics and laboratory parameters.
Discussion
Itch in ESRD and in HD may be termed uremic itch or
“chronic kidney disease-associated itch” and mostly
occurs chronically as so-called chronic itch (CI) [18]. It
has been shown to be an underestimated, burdensome
and therapy-refractory symptom strongly affecting qual-
ity of life [1, 19, 20]. GEHIS is the first representative
cross-sectional study investigating precise prevalence
estimates of CI in HD patients showing that 25.2 % are
affected and that 35.2 % ever experienced CI in life 1].
This is also the very first study that used the inter-
national classification of CI in hemodialysis patients [2].
The current analyses confirm previous research about
the high frequency of comorbidities like congestive heart
failure and hypertension in HD patients. Unlike others
showing significant differences between patients with
and without CI for congestive heart failure and periph-
eral vascular disease (significantly more frequent in
patients with CI), we cannot confirm this. This may be
explained by the large numbers of patients investigated
in the DOPPS study increasing the likelihood of detect-
ing significant differences [3, 5]. Whereas others found a
higher prevalence of itch in HD patients with liver dis-
ease the proportion of patients with liver disease was
small in our study [4]. In this study from Turkey, which,
however is not a representative one, 20 % of all patients
investigated suffered either from Hepatitis B or C. As
liver diseases can also cause itch, other aetiologies of itch
need to be considered in this cohort. A previous study
showed itch not to be significantly different between dia-
betic and non-diabetic HD patients [21] but this result is
in contradiction to other studies, which found a higher
prevalence in diabetic patients [3, 5, 20]. We found CI in
diabetic patients (with and without complications) to be
significantly less prevalent which is an unexpected and
striking finding. However, it was shown that neuropathy
was significantly more common in HD patients with itch
[21] and one study reported 27 % having a history of
neuropathy [22]. As diabetics frequently suffer from
neuropathy and report mixed sensations such as burn-
ing, stinging, pain, this may explain why itch is not the
dominating symptom and was less prevalent in our co-
hort. Due to small nerve damage in long-term diabetes,
patients may experience reduced sensations of different
nerve stimuli including itch.
Prior investigations suggest optimal dialysis efficacy in
terms of higher Kt/V and better nutrition leading to a
reduction of uremic itch [23]. It is necessary to emphasize,
however, that the Kt/V of patients in this study was
increased from mean 1.05 to 1.24, a baseline Kt/V that is
considered insufficient according to the valid European
Best Practice Guidelines. Our results confirm previous
research reporting no difference in the quantity of dialysis
expressed by Kt/V between patients with and without itch,
but these studies did not specifically investigate CI accord-
ing to the international classification [21, 24]. In contrast,
others identified higher Kt/V in patients with itch [7]. The
elevated levels of parathormone (PTH) and phosphorus in
patients with CI of our study partly confirm previous
studies but serum calcium was also higher in these
studies [3, 5, 7]. While phosphorus levels are instable
and influenced by diet, phosphate binders, vitamin D
supplementation, and dialysis, creatinine in part reflects
muscle mass tending to be higher in younger patients.
This is of special interest because in our cohort youn-
ger HD patients were more frequently affected by CI
[1]. Elevated PTH on the other hand has been sus-
pected to be involved into the pathogenesis of CI in
HD patients mainly due to the observation that patients
suffering from distinct hyperparathyreoidism with itch
have experienced complete relief of itch after parathyr-
eoidectomy but PTH never proved a pruritic potency
and the role of PTH in the pathogenesis of CI in dialy-
sis patients is still a matter of debate [18, 25, 26]. Our
study is in line with others who did not detect any sig-
nificant differences between HD patients with and
without itch regarding laboratory parameters such as
Table 4 Type of dialyzer membrane used in hemodialysis patients with and without chronic itch (n = 848)
Dialyzer membrane Total number of used dialyzer membrane Chronic itch according to dialyzer membrane, relative frequency (n)
Yes (12-month prevalence) No
polysulfone, % (n) 63.3 (544) 25.4 (138) 74.6 (406)
polyethersulfone, % (n) 9.9 (85) 24.7 (21) 75.3 (64)
polyarylethersulfone, % (n) 24.5 (211) 33.6 (71)* 66.4 (140)
polyacrylonitrile, % (n) 0.1 (1) - 100.0 (1)
polyester polymer, % (n) - -
polymethylmethacrylate, % (n) 0.8 (7) 28.6 (2) 71.4 (5)
12-month prevalence 25.2 (215)
*Significantly different at p < 0.05
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serum calcium, sodium, potassium, albumin [4, 21].
CRP was not increased in patients with CI compared with
patients without CI which is in contrast to observations in
small previous studies [27, 28]. As the number of HD pa-
tients investigated in GEHIS is representative and the
largest that ever determined CRP, the role of CRP may
have been overestimated in the pathogenesis of CI in
hemodialysis in the past. In summary, the significant dif-
ference concerning PTH, creatinine and phosphorus are
unlikely to explain why 25 % of HD patients still suffer
from CI.
So far, there is no systematic study investigating the
role of dialyzer membranes and the development of
itch, especially chronic itch. A smaller study observed
that patients dialyzed with polysulfone membranes suf-
fered significantly more frequent from CI than those on
hemophane and cuprophane membranes 11]. Others
did not find any correlation between itch and the type
of dialysis membrane used 7]. We identified signifi-
cantly reduced CI in patients treated with a polysulfone
dialyzer (lifetime prevalence) and significantly more
frequent CI when they were dialyzed with polyary-
lethersulfone membranes (all prevalence estimates).
Unfortunately we could not obtain any information in
these HD patients about previous membrane material
used for HD and on the percentage of patients being
switched to other filter materials because they complained
about itch. One may explain this discrepancy with the fact
that meanwhile quality and efficiency of disposables have
continuously been improved and therefore findings of
older studies have to be transferred with great caution. As
previously reported the use of synthetic and high-flux dia-
lyzer membranes significantly increased and this may indi-
cate an effect on the prevalence of CI [3, 5, 9]. Since we
did not assess the consecutive volume used within the
process of hemodiafiltration, this also remains to be inves-
tigated. These aspects influence the impact of the results
on dialyses membranes which have to be interpreted with
caution but should definitely encourage future research
on this aspect of CI in HD patients.
Heparin respectively the type of heparin used during
HD treatment has not been reported to be relevant for CI
in HD patients but interestingly, heparin treatment was
suggested for treatment of uremic itching [29, 30]. We are
not aware of any study that ever investigated heparin use
in a large cohort of HD patients like we did now. It must
be considered that, just as with the membrane material
used, the type of heparin may have been changed once a
patient complained about itch but this was not docu-
mented by any hemodialysis unit. Moreover, the number
of patients treated with low molecular heparin was very
small compared to the ones who received unfractionated
heparin but nevertheless this is a very interesting observa-
tion that needs further investigation.
Conclusions
As previously discussed some limitations of the study
need to be considered and for the current analyses the
following ones need to be mentioned [1]. We were not
able to include every HD patient in large dialysis units
because patient recruiting had to be finished within
each dialysis unit after reaching the sufficient number
of patients according to the study design (cluster sam-
pling). Critically or acutely ill dialysis patients were not
included in this study because acute dialysis units
within emergency departments were excluded. This
aspect is an ancillary limitation because we aimed to in-
vestigate the prevalence of CI in HD patients and not
itch in acute renal insufficiency. As data were obtained
by self-reporting, a bias due to social desirability is pos-
sible. A potential information bias may also apply to
variables analyzed in this study due to patients’ mis-
classification of the outcome variable. HD patients take
many different drugs, some may influence lab values
e.g. PTH, and some may be considered as a potential
trigger of CI [31]. Besides, some patients may have
taken anti-itch medication. As our sample is represen-
tative and chronic itch (CI) (not acute itch) was
addressed, we believe that these aspects can be less
considered. Our study adds new findings in the field of
epidemiological studies on CI in hemodialysis. Due to
the comparability concerning standards in quality of
dialysis in developed countries, our study results can be
transferred to other Western countries. The first find-
ings of GEHIS indicate CI to occur more frequently in
HD patients of younger age, having an etiology of ESRD
of primary chronic glomerulonephritis and a history of
eczema and dry skin [1]. New analyses show that dia-
betes is associated with a lower prevalence of CI. We
found evidence that the time on HD is associated with
a higher prevalence of CI as well as the type of dialyzer
membranes used. The elevated levels of PTH, phos-
phorus and creatinine may represent an epiphenom-
enon only associated with CI but related to the
pathophysiological situation in hemodialysis. All this
contributes to the assumption that the pathogenesis of
CI in hemodialysis is considered as unclear [18] and we
can now add that chronic itch in hemodialysis is prob-
ably of multifactorial origin. It is most likely that sev-
eral factors e.g. PTH elevation, origin of ESRD, type of
dialysis membrane, type of heparin used for anticoagu-
lation and a neuropathic component all contribute to
the occurrence of CI in HD. All these possible patho-
genic factors need to be investigated in future studies.
As we could show in another study that the 12-month
incidence of CI equals 7 % even in the general popula-
tion, one has to face that there is a constant number of
new itch cases in HD which will without much doubt
be higher than in the general population [32].
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